Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $165 | In Stock | |
5 mg | $413 | In Stock | |
10 mg | $689 | In Stock | |
25 mg | $1,490 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,500 | In Stock | |
1 mL x 10 mM (in DMSO) | $473 | In Stock |
Description | Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer. |
In vitro | Ralaniten triacetate (EPI-506) is a highly specific small molecule targeting the N-terminal domain (NTD) of the androgen receptor (AR). It is commonly used in research on metastatic castration-resistant prostate cancer (mCRPC), where resistance to androgen deprivation therapy has developed[2]. |
Alias | EPI-506 |
Molecular Weight | 521.00 |
Formula | C27H33ClO8 |
Cas No. | 1637573-04-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (153.55 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.